Afstyla (lonoctocog alfa) for hemophilia
Afstyla (lonoctocog alfa) is an injectable factor replacement therapy used to prevent and treat bleeding episodes, including those occurring during surgery, in people with hemophilia A.
Search results for:
Kovaltry (octocog alfa) for hemophilia
Kovaltry (octocog alfa) is a recombinant, or man-made, antihemophilic factor therapy that is approved to prevent and treat bleeding episodes, including those occurring during surgery, in adults and children with hemophilia A.
Rebinyn (nonacog beta pegol) for hemophilia
Rebinyn (nonacog beta pegol, or N9-GP) is an extended half-life product approved for treating and preventing bleeds, including those occurring during surgery, in adults and children with hemophilia B.
How to celebrate the holidays while you handle your hemophilia
Every year, the holiday season appears to arrive earlier, a stark contrast to the days when Christmas wasn’t even contemplated until after Thanksgiving. Now, the hustle and bustle of preparations begin as early as Halloween. This year, the approaching holiday season carries a bittersweet weight for me as it’ll be…
How lessons from hemophilia help me during a busier-than-usual time
The past three weeks have been busy ones in the life of my church family. Since the middle of last month, I’ve performed four funerals and a wedding and led a critical church conference. These events have had emotional consequences. My anxiety level continues to be high as I navigate…
FEIBA (factor eight inhibitor bypassing activity) for hemophilia
FEIBA is an approved treatment for patients with hemophilia A and B, some of whom may have stopped responding to replacement therapy.
Health Canada approves Hemgenix gene therapy for hemophilia B
Health Canada has approved the gene therapy Hemgenix (etranacogene dezaparvovec) for treating adults with hemophilia B who rely on routine prophylactic therapies to prevent or reduce bleeding episodes. Hemgenix is now the first and only gene therapy available to this patient group. “The approval of Hemgenix in Canada…
Esperoct (turoctocog alfa pegol) for hemophilia
Read about Esperoct, an extended half-life infusion treatment approved to prevent or stop bleeding in children and adults with hemophilia A.
Mild is the most dangerous word in the classification of hemophilia
The recent Rare Blood Disease Summit sponsored by Genentech highlighted a critical perspective pertinent to me: “Mild is the most dangerous word in hemophilia.” I wholeheartedly agree with this statement as a person with mild hemophilia B and von Willebrand disease. Mild hemophilia is distinguished…
What is hemophilia?
Hemophilia is a rare disorder in which a person’s blood is not able to clot properly, resulting in unusually easy and prolonged bleeding.